Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma

Archives of Ophthalmology

Volumn 121, Issue 5, 2003, Pages 615-620

  Lambiase, Alessandro ^a,b   Bonini, Stefano ^a,b   Rasi, Guido ^c   Coassin, Marco ^a   Bruscolini, Alice ^a   Bonini, Sergio ^c,d  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADOLESCENT; ADULT; ALLERGIC REACTION; ARTICLE; ASTHMA; CHEMOSIS; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPIRATORY FLOW; FEMALE; FOREIGN BODY REACTION; HUMAN; HYPEREMIA; HYPERSENSITIVITY REACTION; KERATOCONJUNCTIVITIS; LACRIMATION; MALE; PHOTOPHOBIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ACETATES; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, ALLERGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE B4; LEUKOTRIENE E4; MALE; OPHTHALMIC SOLUTIONS; PEAK EXPIRATORY FLOW RATE; PILOT PROJECTS; QUINOLINES; TEARS;

EID: 0038667899     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.5.615     Document Type: Article

References (39)

1. Buckley RJ. Vernal keratoconjunctivitis. Int Ophthalmol Clin. 1988;28:303-308.
2. Bielory L, Frohman LP. Allergic and immunologic disorders of the eye. J Allergy Clin Immunol. 1992;89:1-15.
3. Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000;107:1157-1163.
4. Easty DL, Birkenshaw M, Merrett T, Merrett J, Entwhistle C, Amer B. Immunological investigations in vernal eye disease. Trans Ophthalmol Soc U K. 1980; 100:98-107.
5. Friedlaender MH. Ocular allergy. J Allergy Clin Immunol. 1985;76:645-657.
6. Bonini S, Bonini S. IgE and non-IgE mechanisms in ocular allergy. Ann Allergy. 1993;71:296-299.
7. Coombs RRA, Gell PGH. The classification of allergic reactions underlying disease. In: Gell PGH, Coombs RRA, eds. Clinical Aspects of Immunology. Oxford, England: Blackwell Scientific Publications; 1962:chap 13.
8. Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis: a model of 5q cytokine gene cluster disease. Int Arch Allergy Immunol. 1995;107:95-98.
9. Bhattacheriee P. The role of arachidonate metabolites in ocular inflammation. Prog Clin Biol Res. 1989;312:211-227.
10. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993;38(suppl): 115-132.
11. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol. 1997;99 (suppl):S763-S772.
12. Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes LTC4 and LTB4 in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989;84:19-26.
13. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway [published corrections aappear in N Engl J Med. 1999;340: 663 and N Engl J Med. 1999;341:1632]. N Engl J Med. 1999;340:197-206.
14. Miadonna A, Tedeschi A, Leggieri E, etal. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis. 1987;136:357-362.
15. Creticos PS, Peters SP, Adkinson NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med. 1984;310:1626-1630.
16. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosa blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy. 1986;16:289-297.
17. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990;323:1745-1748.
18. Marom Z, Shelhamen JH, Kaliner M. Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airway in vitro. J Clin Invest. 1981;67:1695-1702.
19. Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 1996;98:528-534.
20. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147-152.
21. Lipworth BJ. Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp Allergy. 2001;31:1813-1821.
22. Sander C, Rajakulasingam K. Leukotriene receptor antagonists for the treatment of allergic rhinitis. Clin Exp Allergy. 2002;32:4-7.
23. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31:1385-1391.
24. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy. 2001;31: 1607-1614.
25. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol. 2001;12:154-158.
26. 4 in man: urinary excretion of leukotriene E4. Biochem Biophys Res Commun. 1985;130:214-220.
27. Akman A, Irkec M, Orhan M. Effects of Iodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye. 1998;12:291-295.
28. Nathan H, Naveh N, Meyer E. Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin. Doc Ophthalmol. 1994;85:247-257.
29. Kulkarni PS, Srinivason BD. Synthesis of slow reacting substance-like activity in rabbit conjunctiva and anterior uvea. Invest Ophthalmol Vis Sci. 1983;24:1079-1085.
30. Irkec M, Orhan M. Effect of extended wear disposable contact lenses on tear LTC4 in giant papillary conjunctivitis. Ocul Immunol Inflamm. 1995;3:107-111.
31. Proud D, Sweet J, Stein P, et al. Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J Allergy Clin Immunol. 1990;85:896-905.
32. Bisgaard H, Ford-Hutchinson AW, Charleson S, Taudorf E. Detection of leukotriene C4-like immunoreactivity in tear fluid from subjects challenged with specific allergen. Prostaglandins. 1984;27:369-374.
33. Bisgaard H, Ford-Hutchinson AW, Charleson S, Taudorf E. Production of leukotrienes in human skin and conjunctival mucosa after specific allergen challenge. Allergy. 1985;40:417-423.
34. Spada CS, Woodward DF, Hawley SB, Nieves AL. Leukotrienes cause eosinophil emigration into conjunctival tissue. Prostaglandins. 1986;31:795-809.
35. Woodward DF, Ledgard SE. Effect of LTD4 on conjunctival vasopermeability and blood-aqueous barrier integrity. Invest Ophthalmol Vis Sci. 1985;26:481-485.
36. Gary RK Jr, Woodward DF, Nieves AL, Williams LS, Gleason JG, Wasserman MA, Characterization of the conjunctival vasopermeability response to leukotrienes and their involvement in immediate hypersensitivity. Invest Ophthalmol Vis Sci. 1988;29:119-126.
37. Sampson AP, Castling DP, Green CP, Price JF. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child. 1995;73:221-225.
38. Volovitz B, Tabachnik E, Nussinovitch M, et al. Montelukast, a leukatriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol. 1999;104:1162-1167.
39. Bonini S, Tommassini M, Bonini S, Capron M, Balsano F. The eosinophil has a pivotal role in allergic inflammation of the eye. Int Arch Allergy Immunol. 1992; 99:354-358.